Dr. Rahul Kumar
Profile: Rahul did his MSc (Biotechnology) from AIIMS, New Delhi (2010) and PhD (Bioinformatics) from CSIR-IMTECH, Chandigarh (2015). In his PhD, he worked on developing biological databases and machine learning based prediction models to design anticancer therapeutics. Then he joined Institute of Cancer Research (ICR), London and worked on identification of synthetic lethal interactions using high throughput genomic technologies. Then he joined Memorial Sloan Kettering Cancer Center (MSKCC), New York and worked on genetics of rare form of breast cancers to identify their putative genetic drivers. Later he joined Columbia University Irving Medical Center (CUIMC), New York as a scientist and focused on non-coding genome of diffuse large B-cell lymphoma (DLBCL). Rahul joined CBR in 2021 and his research focus is on non-coding genome of Alzheimer’s disease (AD) and other brain related diseases.
My lab is actively working in the CBR’s key projects i.e., Srinivaspura Aging Neuro Senescence and Cognition Study (SANSCOG), TATA Longitudinal Study of Aging (TLSA) and Genome India (GI). We are interested in Genome Wide Association Studies (GWAS) using in-house genotype data generated for the subjects recruited in various CBR’s projects. We are looking for the association between genotypes and biochemical parameters obtained from the blood profiling e.g., homocysteine, Vitamin B12 etc.
We are also interested in the non-coding genome to understand the genetic architecture of Alzheimer’s disease (AD). We are specifically interested in genomic alteration in enhancer/super-enhancer regions and how they are dysregulating the expression of target genes which are possibly involved in AD pathogenesis.
Along with other CBR faculty members, clinical fellows and collaborators at NIMHANS, Bengaluru, we are building another project to better understand the genetics of familial Parkinson’s disease (PD).
- Riaz N., Sherman E., …Kumar R., et al (2020). Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. JNCI: Journal of National Cancer Institute.
- Pareja, F., Lee J. Y., Gularte-Mérida, R., Selenica P., Brown, D.N., Da Cruz Paula, A.,Kumar R., et al (2019). The genomic landscape of mucinous breast cancer.JNCI: Journal of National Cancer Institute.111:737:74.
- Pareja, F., …Kumar R., et al (2019). Loss-of-function mutations in the pH regulators ATP6AP1 and ATP6AP2 in granular cell tumors. 9:3533. Nature Communications
- Mandelker, D.L.*,Kumar R.*, Weigelt, B.* et. al. (2019). The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers. JNCI Cancer Spectrum3(2):pkz027.
- Selenica P.*, Raj N.*,Kumar R.*,et. al. (2019).Solid pseudopapillary neoplasm of the pancreas are dependent on the Wnt pathway. Molecular Oncology. 13:1684-1692.
- Weigelt, B.*, Bi, R.*,Kumar R.*, et. al. (2018)., The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. JNCI: Journal of National Cancer Institute.110:1030-1034.
- Ashley C., Paula A. D. C., Kumar R. , et. al. (2018), Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. Gynecologic Oncology.152(1):11-19.
- Mueller, J.J., Schlappe, B.A.,Kumar R.,et. al.(2018). Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. Gynecologic Oncology.150, 127–135.
- Brough, R., Gulati, A., Haider, S., Kumar R., et. al. (2018). Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. Oncogene.
- Geyer, F.C., …Kumar R., et. al. (2018). Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nature Communications.9:1816
- Bajrami, I., ….Kumar R., et. al. (2018). E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.Cancer Discovery. 8, 498–515.
- Nikkilä, J.,Kumar R., et. al. (2017). Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.British Journal of Cancer117, 113–123.
- Kumar R., and Raghava, G.P.S. (2016). ApoCanD: Database of human apoptotic proteins in the context of cancer.Scientific Reports117, 113–123.
- Singh Nanda,J.*,Kumar R., et. al. (2016). dbEM: A database of epigenetic modifiers curated from cancerous and normal genomes.Scientific Reports6, 19340.
- Kumar R., et. al. (2014a). Designing of promiscuous inhibitors against pancreatic cancer cell lines.Scientific Reports4, 4668.
- Kumar R., et. al. (2013a). CancerDR: Cancer Drug Resistance Database.Scientific Reports3, 1445.
- Kumar R., et. al. In Silico Designing and Screening of Antagonists against Cancer Drug Target XIAP.Current Cancer Drug Targets 15, 836–846.
- Holmes A. B., Corinaldesi C., Shen Q., Kumar R. Single-cell analysis identifies subpopulations of germinal-center B-cells informing on lymphoma cell-of-origin and outcome.Journal of Experimental Medicine.
Google Scholar profile: Link for the Google Scholar Profile
Centre for Brain Research
Indian Institute of Science (IISc)
Malleswaram 18th Cross
Telephone: Office +91 80 2293 3659